Crit Care Med 2009;37, 1929-1934
Phase 2 clinical trials involved 338 adults with obesity (BMI 30 or more) and overweight (BMI of 2729.99) with one or more weight-related conditions such as high blood pressure, high cholesterol levels, heart disease, and type 2 diabetes
Public awareness of GLP-1 medications has surged alongside their adoption, with approximately 91% of respondents in 2026 saying they knew the drugs could be used to treat weight loss, compared with 80% in 2024
For the glycine biosensor, we took advantage of this system by swapping out the gcvB gene with an RFP reporter to produce a glycine biosensor
The compounds don't affect gastric motility or satiety signaling
Extremely clean facility, fast service, and truly caring medical staff